References
1. Terasaki PI. Humoral theory of transplantation. Am J Transpl. 2003;3(6):665–73.
2. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N Engl J Med. 2010;363(15):1451–62.
3. Mohan S, Palanisamy A, Tsapepas D, Tanriover B, Crew RJ, Dube G, et al. Donor-Specific Antibodies Adversely Affect Kidney Allograft Outcomes. J Am Soc Nephrol. 2012;23(12):2061–71.
4. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transpl. 2012;12(2):388–99.
5. Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. J Clin Invest. 2017;127(7):2492–504.
6. Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana J, et al. Correction: Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis. PLOS Med. 2018;15(7):e1002572.
7. Loupy A, Lefaucheur C. Antibody-Mediated Rejection of Solid-Organ Allografts. N Engl J Med. 2018;379(12):1150–60.
8. Valenzuela NM, Hickey MJ, Reed EF. Antibody Subclass Repertoire and Graft Outcome Following Solid Organ Transplantation. Front Immunol. 2016;7:433.
9. Papadimitriou JC, Drachenberg CB, Ramos E, Kukuruga D, Klassen DK, Ugarte R, et al. Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. Transplantation. 2013;95(1):128–36.
10. Lefaucheur C, Viglietti D, Bentlejewski C, van Huyen J-P, Vernerey D, Aubert O, et al. IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. J Am Soc Nephrol Jasn. 2016;27(1):293–304.
11. Valenzuela NM, Schaub S. The Biology of IgG Subclasses and Their Clinical Relevance to Transplantation. Transplantation. 2018;102(1S):S7–13.
12. Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015;67(2 Pt A):171–82.
13. Reimer CB, Phillips DJ, Aloisio CH, Moore DD, Galland GG, Wells TW, et al. Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma. 1984;3(3):263–75.
14. Jackson AM, Kanaparthi S, Burrell BE, Lucas DP, Vega RM, Demetris AJ, et al. IgG4 donor-specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg. 2019;20(2):513–24.
15. Lowe D, Higgins R, Zehnder D, Briggs DC. Significant IgG subclass heterogeneity in HLA-specific antibodies: Implications for pathogenicity, prognosis, and the rejection response. Hum Immunol. 2013;74(5):666–72.
16. Kaneku H, G, O’Leary J, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB. Donor‐specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation. Liver Transpl. 2012;18(8):984–92.
17. Cicciarelli JC, Lemp NA, Chang Y, Koss M, Hacke K, Kasahara N, et al. Renal Transplant Patients Biopsied for Cause and Tested for C4d, DSA, and IgG Subclasses and C1q: Which Humoral Markers Improve Diagnosis and Outcomes? J Immunol Res. 2017;2017:1–14.
18. Ravindranath MH, Jucaud V, Banuelos N, Everly MJ, Cai J, Nguyen A, et al. Nature and Clonality of the Fluoresceinated Secondary Antibody in Luminex Multiplex Bead Assays Are Critical Factors for Reliable Monitoring of Serum {HLA} Antibody Levels in Patients for Donor Organ Selection, Desensitization Therapy, and Assessment of t. J Immunol. 2017;198(11):4524–38.
19. von Ponsirenas R, Cazarote HB, de Araújo S, Wanderley D, Shimakura S, Valdameri JS, et al. Anti-HLA Donor-Specific IgG Subclasses and C1q-binding Evolution in Posttransplant Monitoring. Transpl Direct. 2018;4(9):e385.
20. Navas A, Molina J, Agüera M-L, Guler I, Jurado A, Rodríguez-Benot A, et al. Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays. Front Immunol. 2019;10:1712.
21. Khovanova N, Daga S, Shaikhina T, Krishnan N, Jones J, Zehnder D, et al. Subclass analysis of donor HLA‐specific IgG in antibody‐incompatible renal transplantation reveals a significant association of IgG4 with rejection and graft failure. Transpl Int. 2015;28(12):1405–15.
22. Hamdani G, Goebel JW, Brailey P, Portwood EA, Hooper DK, Girnita AL. IGG3 anti-HLA donor-specific antibodies and graft function in pediatric kidney transplant recipients. Pediatr Transpl. 2018;22(5):e13219.
23. O’Leary J, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 Subclass and C1q‐Fixing Donor‐Specific HLA Alloantibodies on Rejection and Survival in Liver Transplantation. Am J Transpl. 2015;15(4):1003–13.
24. Freitas MS, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, et al. The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation Outcomes. Transplantation. 2013;95(9):1113.
25. Sullivan HC, Gebel HM, Bray RA. Understanding solid-phase HLA antibody assays and the value of MFI. Hum Immunol. 2017;
26. Sullivan HC, Liwski RS, Bray RA, Gebel HM. The Road to HLA Antibody Evaluation: Do Not Rely on MFI. Am J Transpl. 2017;
27. Archdeacon P, Chan M, Neuland C, Velidedeoglu E, Meyer J, Tracy L, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transpl. 2011;11(5):896–906.
28. Tambur AR, Herrera ND, Haarberg KM, Cusick MF, Gordon RA, Leventhal JR, et al. Assessing Antibody Strength: Comparison of {MFI,} C1q, and Titer Information. 2015;15(9):2421–30.
29. Ravindranath MH, Terasaki PI, Maehara CY, Jucaud V, Kawakita S, Pham T, et al. Immunoglobulin {(Ig)G} purified from human sera mirrors intravenous Ig human leucocyte antigen {(HLA)} reactivity and recognizes one’s own {HLA} types, but may be masked by Fab complementarity-determining region peptide in the native sera. 2015;179(2):309–28.
30. Jefferis R, Lefranc M-P. Human immunoglobulin allotypes. MAbs. 2009;1(4):332–8.
31. Kramer CSM, Dijk MEI, Priddey AJ, Pongrácz T, Gnudi E, Car H, et al. Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of donor-specific antibodies. Hla. 2019;94(5):415–24.
32. Everly MJ, Rebellato LM, Haisch CE, Briley KP, Bolin P, Kendrick WT, et al. Impact of IgM and IgG3 Anti-HLA Alloantibodies in Primary Renal Allograft Recipients. Transplantation. 2014;97(5):494–501.